UNIVERSITE PARIS DIDEROT - PARIS 7;URGO RECHERCHE INNOVA;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS;ECOLE NORMALE SUPERIEURE;INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HICl, FOXSl, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.